Cargando…

An overview of structure-based activity outcomes of pyran derivatives against Alzheimer’s disease

Pyran is a heterocyclic group containing oxygen that possesses a variety of pharmacological effects. Pyran is also one of the most prevalent structural subunits in natural products, such as xanthones, coumarins, flavonoids, benzopyrans, etc. Additionally demonstrating the neuroprotective properties...

Descripción completa

Detalles Bibliográficos
Autor principal: Almalki, Faisal A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205782/
https://www.ncbi.nlm.nih.gov/pubmed/37234350
http://dx.doi.org/10.1016/j.jsps.2023.04.030
_version_ 1785046099537428480
author Almalki, Faisal A.
author_facet Almalki, Faisal A.
author_sort Almalki, Faisal A.
collection PubMed
description Pyran is a heterocyclic group containing oxygen that possesses a variety of pharmacological effects. Pyran is also one of the most prevalent structural subunits in natural products, such as xanthones, coumarins, flavonoids, benzopyrans, etc. Additionally demonstrating the neuroprotective properties of pyrans is the fact that this heterocycle has recently attracted the attention of scientists worldwide. Alzheimer's Disease (AD) treatment and diagnosis are two of the most critical research objectives worldwide. Increased amounts of extracellular senile plaques, intracellular neurofibrillary tangles, and a progressive shutdown of cholinergic basal forebrain neuron transmission are often related with cognitive impairment. This review highlights the various pyran scaffolds of natural and synthetic origin that are effective in the treatment of AD. For better understanding synthetic compounds are categorized as different types of pyran derivatives like chromene, flavone, xanthone, xanthene, etc. The discussion encompasses both the structure–activity correlations of these compounds as well as their activity against AD. Because of the intriguing actions that were uncovered by these pyran-based scaffolds, there is no question that they are at the forefront of the search for potential medication candidates that could treat Alzheimer's disease.
format Online
Article
Text
id pubmed-10205782
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102057822023-05-25 An overview of structure-based activity outcomes of pyran derivatives against Alzheimer’s disease Almalki, Faisal A. Saudi Pharm J Review Pyran is a heterocyclic group containing oxygen that possesses a variety of pharmacological effects. Pyran is also one of the most prevalent structural subunits in natural products, such as xanthones, coumarins, flavonoids, benzopyrans, etc. Additionally demonstrating the neuroprotective properties of pyrans is the fact that this heterocycle has recently attracted the attention of scientists worldwide. Alzheimer's Disease (AD) treatment and diagnosis are two of the most critical research objectives worldwide. Increased amounts of extracellular senile plaques, intracellular neurofibrillary tangles, and a progressive shutdown of cholinergic basal forebrain neuron transmission are often related with cognitive impairment. This review highlights the various pyran scaffolds of natural and synthetic origin that are effective in the treatment of AD. For better understanding synthetic compounds are categorized as different types of pyran derivatives like chromene, flavone, xanthone, xanthene, etc. The discussion encompasses both the structure–activity correlations of these compounds as well as their activity against AD. Because of the intriguing actions that were uncovered by these pyran-based scaffolds, there is no question that they are at the forefront of the search for potential medication candidates that could treat Alzheimer's disease. Elsevier 2023-06 2023-05-08 /pmc/articles/PMC10205782/ /pubmed/37234350 http://dx.doi.org/10.1016/j.jsps.2023.04.030 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Almalki, Faisal A.
An overview of structure-based activity outcomes of pyran derivatives against Alzheimer’s disease
title An overview of structure-based activity outcomes of pyran derivatives against Alzheimer’s disease
title_full An overview of structure-based activity outcomes of pyran derivatives against Alzheimer’s disease
title_fullStr An overview of structure-based activity outcomes of pyran derivatives against Alzheimer’s disease
title_full_unstemmed An overview of structure-based activity outcomes of pyran derivatives against Alzheimer’s disease
title_short An overview of structure-based activity outcomes of pyran derivatives against Alzheimer’s disease
title_sort overview of structure-based activity outcomes of pyran derivatives against alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205782/
https://www.ncbi.nlm.nih.gov/pubmed/37234350
http://dx.doi.org/10.1016/j.jsps.2023.04.030
work_keys_str_mv AT almalkifaisala anoverviewofstructurebasedactivityoutcomesofpyranderivativesagainstalzheimersdisease
AT almalkifaisala overviewofstructurebasedactivityoutcomesofpyranderivativesagainstalzheimersdisease